Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Actinium Pharmaceuticals, Inc., a biotechnology company, develops drugs for the treatment of cancer. The company develops therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform. Its products include Bismab-A for acute myeloid leukemia; Actimab-A, an antibody-drug construct that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia; and Iomab-B, an antibody-drug construct used in myeloconditioning for hematopoietic stem cells transplantation in various indications. The company was formerly known as Cactus Ventures, Inc. and changed its name to Actinium Pharmaceuticals, Inc. in April 2013. Actinium Pharmaceuticals, Inc. was founded in 2000 and is based in New York, New York.
|Shares Outstanding||EPS||-0.54||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E||-2.07|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-55.16%||ROE||-67.28%||ROI|
|Current Ratio||5.52||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.22|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||18.39 M||Cash From Investing Activities||Cash From Operating Activities||-5.81 M||Gross Profit|
|Net Profit||-3.07 M||Operating Profit||-7.87 M||Total Assets||20.06 M||Total Current Assets||19.92 M|
|Total Current Liabilities||3.61 M||Total Debt||190 K||Total Liabilities||3.61 M||Total Revenue|
|High 52 week||0.82||Low 52 week||0.2||Last close||0.2||Last change||-0.51%|
|RSI||9.3||Average true range||0.01||Beta||1.17||Volume||288.91 K|
|Simple moving average 20 days||-9.47%||Simple moving average 50 days||-11.28%||Simple moving average 200 days||-48.79%|
|Performance Week||-1.99%||Performance Month||-14.72%||Performance Quart||-14.35%||Performance Half||-60.84%|
|Performance Year||-75.01%||Performance Year-to-date||-49.1%||Volatility daily||2.73%||Volatility weekly||6.11%|
|Volatility monthly||12.52%||Volatility yearly||43.36%||Relative Volume||353.16%||Average Volume||632.42 K|
|New High||New Low|
2020-04-21 23:35:00 | Actinium Pharmaceuticals, Inc. Announces Pricing of $27.5 Million Public Offering
2020-04-21 16:01:00 | Actinium Pharmaceuticals, Inc. Announces Proposed Public Offering
2020-04-12 09:02:20 | Can Actinium Pharmaceuticals NYSEMKT:ATNM Afford To Invest In Growth?
2020-03-06 10:56:03 | Actinium Treats First Patient in AML Study on Actimab-A Combo
2020-02-25 09:33:02 | Actinium ATNM to Report Q4 Earnings: What's in the Cards?
2020-02-13 08:03:00 | Actinium to Highlight Targeted Conditioning Portfolio at 2020 Transplantation & Cellular Therapy Annual Meeting; Phase 3 SIERRA Trial Preliminary Results Selected for Oral Presentation
2020-02-05 17:50:10 | Actinium Pharmaceuticals ATNM Gains But Lags Market: What You Should Know
2020-01-30 17:45:10 | Actinium Pharmaceuticals ATNM Stock Sinks As Market Gains: What You Should Know
2020-01-13 12:00:05 | Actinium ATNM Upgraded to Strong Buy: Here's Why
2020-01-13 07:15:17 | One Thing To Remember About The Actinium Pharmaceuticals, Inc. NYSEMKT:ATNM Share Price
2020-01-07 07:03:00 | Actinium Pharmaceuticals, Inc. to Present at 2020 Biotech Showcase™
2020-01-03 11:30:04 | Is Actinium Pharmaceuticals ATNM Outperforming Other Medical Stocks This Year?
2020-01-02 09:29:02 | Tilray TLRY in Focus: Stock Moves 9% Higher
2019-12-22 17:08:58 | Hedge Funds Have Never Been More Bullish On Actinium Pharmaceuticals Inc ATNM
2019-12-09 06:10:00 | Actinium Pharmaceuticals Highlights 86% Response Rate and 71% MRD Negative Rate in Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML at ASH 2019 Annual Meeting
2019-12-07 08:35:07 | The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling
2019-12-01 09:30:15 | The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More
2019-11-20 09:00:02 | What Makes Actinium ATNM a New Buy Stock
2019-11-06 09:00:00 | Actinium Pharmaceuticals to Present New Clinical Findings from SIERRA Trial Supporting the Iomab-ACT Program for Targeted Lymphodepletion for CAR-T and Adoptive Cell Therapies at ASH 2019
2019-10-15 10:48:01 | What Kind Of Investor Owns Most Of Actinium Pharmaceuticals, Inc. NYSEMKT:ATNM?
2019-09-30 08:00:00 | Actinium Announces Participation at the 2019 Cell & Gene Meeting on the Mesa
2019-07-17 12:56:33 | How Actinium Pharmaceuticals, Inc. NYSEMKT:ATNM Can Impact Your Portfolio Volatility
2019-06-20 08:00:00 | Actinium's Portfolio of Antibody Radiation-Conjugates to be Highlighted in Two Oral and Two Poster Presentations at the 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting
2019-06-04 08:00:00 | Actinium Presents New Pivotal Phase 3 SIERRA Trial Data Showing Rapid Peripheral Blast Reduction and Anti-Leukemic Effect with Single Agent Iomab-B in Older Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia at 2019 ASCO Annual Meeting
2019-05-07 08:00:00 | Actinium Announces Appointment of Niva Almaula, Ph.D. as Chief Business Officer
2019-04-03 09:16:01 | Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy